BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 9889060)

  • 1. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
    Zervos EE; Shafii AE; Rosemurgy AS
    J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.
    Zervos EE; Shafii AE; Haq M; Rosemurgy AS
    J Surg Res; 1999 Jun; 84(2):162-7. PubMed ID: 10357914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.
    Zervos EE; Norman JG; Gower WR; Franz MG; Rosemurgy AS
    J Surg Res; 1997 May; 69(2):367-71. PubMed ID: 9224409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs.
    Haq M; Shaeii AE; Zervos EE; Rosemurgy AS
    Int J Surg Investig; 2000; 1(6):459-65. PubMed ID: 11729853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
    Low JA; Johnson MD; Bone EA; Dickson RB
    Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line.
    Wu AJ; Lafrenie RM; Park C; Apinhasmit W; Chen ZJ; Birkedal-Hansen H; Yamada KM; Stetler-Stevenson WG; Baum BJ
    J Cell Physiol; 1997 May; 171(2):117-24. PubMed ID: 9130458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
    Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
    Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas.
    Matsuyama Y; Takao S; Aikou T
    J Surg Oncol; 2002 Jun; 80(2):105-10. PubMed ID: 12173379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
    Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
    Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20.
    Bu W; Tang ZY; Sun FX; Ye SL; Liu KD; Xue Q; Chen J; Gao DM
    Hepatogastroenterology; 1998; 45(22):1056-61. PubMed ID: 9756006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor.
    Nabeshima K; Inoue T; Shimao Y; Okada Y; Itoh Y; Seiki M; Koono M
    Cancer Res; 2000 Jul; 60(13):3364-9. PubMed ID: 10910039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.
    Haq M; Shafii A; Zervos EE; Rosemurgy AS
    Cancer Res; 2000 Jun; 60(12):3207-11. PubMed ID: 10866312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice.
    Wang X; Fu X; Brown PD; Crimmin MJ; Hoffman RM
    Cancer Res; 1994 Sep; 54(17):4726-8. PubMed ID: 8062271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
    Duivenvoorden WC; Hirte HW; Singh G
    Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
    Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
    Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase.
    Kinoshita T; Sato H; Takino T; Itoh M; Akizawa T; Seiki M
    Cancer Res; 1996 Jun; 56(11):2535-8. PubMed ID: 8653693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis.
    Bloomston M; Shafii A; Zervos EE; Rosemurgy AS
    J Surg Res; 2002 Jan; 102(1):39-44. PubMed ID: 11792150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
    Määttä M; Soini Y; Liakka A; Autio-Harmainen H
    Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.